Publication: 3479

Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials

Citation:: J Clin Oncol vol 36 (16) 1603-10

Year:: 2018
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: ppub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:

Parents:: 2991
Children:: None

Program:: OGC
Primary Committee:: Lymphoma
Sec. Committees:

Pharmas:
Grants:: P30 CA086862, P50 CA097274, U01 CA195568

Corr. Author:: Matthew J. Maurer
Authors:: Matthew J. Maurer Hervé Ghesquières Brian K. Link Jean-Philippe Jais Thomas M. Habermann Carrie A. Thompson Corinne Haioun Cristine Allmer Patrick B. Johnston Richard Delarue Ivana N. Micallef Frederic Peyrade David J. Inwards Nicolas Ketterer Umar Farooq Olivier Fitoussi William R. Macon Thierry J. Molina Sergei Syrbu Andrew L. Feldman Susan L. Slager George J. Weiner Stephen M. Ansell James R. Cerhan Gilles A. Salles Thomas E. Witzig Hervé Tilly Grzegorz S. Nowakowski

Networks:

Study: Alliance-A151814
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: N/A

Keywords:: ORIGINAL REPORTS, Hematologic Malignancy